Concurrent chemoradiation for local advanced esophageal carcinoma

Abstract

Zhang Guangming, Mao Wenkui, Huang Debo, Zhang Xuewei. Concurrent chemoradiation for local advanced esophageal carcinoma[J]. Journal of International Oncology, 2014, 41(8): 595-598.

［1］ Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase Ⅲ trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781［J］. J Clin Oncol, 2008, 26(7): 1086-1092. ［2］ Pasini F, de Manzoni G, Zanoni A, et al. Neoadjuvant therapy with weekly docetaxel and cisplatin, 5fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of longlasting pathological complete response: a phase 2 study［J］. Cancer, 2013, 119(5): 939945. ［3］ van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer［J］. N Engl J Med, 2012, 366(22): 20742084. ［4］ Kranzfelder M, Schuster T, Geinitz H, et al. Metaanalysis of neoadjuvant treatment modalities and definitive nonsurgical therapy for oesophageal squamous cell cancer［J］. Br J Surg, 2011, 98(6): 768-783. ［5］ Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated metaanalysis［J］. Lancet Oncol, 2011, 12(7): 681-692. ［6］ Hong JC, Murphy JD, Wang SJ, et al. Chemoradiotherapy before and after surgery for locally advanced esophageal cancer: a SEERMedicare analysis［J］. Ann Surg Oncol, 2013, 20(12): 3999-4007. ［7］ Pasini F, de Manzoni G, Zanoni A, et al. Neoadjuvant therapy with weekly docetaxel and cisplatin, 5fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of longlasting pathological complete response: a phase 2 study［J］. Cancer, 2013, 119(5): 939-945. ［8］ Spigel DR, Greco FA, Meluch AA, et al. Phase Ⅰ/Ⅱ trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction［J］. J Clin Oncol, 2010, 28(13): 2213-2219. ［9］ Wu S, Chen MY, Luo JC, et al. Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma［J］. Zhonghua Zhong Liu Za Zhi, 2012, 34(11): 873876. ［10］ Blom RL, Sosef MN, Nap M, et al. Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma［J］. Dis Esophagus, 2014, 27(4): 380-387. ［11］ Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 9405) phase Ⅲ trial of combinedmodality therapy for esophageal cancer: highdose versus standarddose radiation therapy［J］. J Clin Oncol, 2002, 20(5): 11671174. ［12］ Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102［J］. J Clin Oncol, 2007, 25(10): 1160-1168. ［13］ Li QQ, Liu MZ, Hu YH, et al. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma［J］. Dis Esophagus, 2010, 23(3): 253-259. ［14］ Tu L, Sun L, Xu Y, et al. Paclitaxel and cisplatin combined with intensitymodulated radiotherapy for upper esophageal carcinoma［J］. Radiat Oncol, 2013, 8: 75. ［15］ Conroy T, Yataghene Y, Etienne PL, et al. Phase Ⅱ randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer［J］. Br J Cancer, 2010, 103(9): 1349-1355. ［16］ Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial［J］. Lancet Oncol, 2014, 15(3): 305-314. ［17］ Iwase H, Shimada M, Tsuzuki T, et al. Concurrent chemoradiotherapy with a novel fluoropyrimidine, S1, and cisplatin for locally advanced esophageal cancer: longterm results of a phase Ⅱ trial［J］. Oncology, 2013, 84(6): 342349. ［18］ Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus［J］. J Clin Oncol, 2005, 23(10): 2310-2317. ［19］ Gwynne S, Hurt C, Evans M, et al. Definitive chemoradiation for oesophageal cancera standard of care in patients with nonmetastatic oesophageal cancer［J］. Clin Oncol (R Coll Radiol), 2011, 23(3): 182-188. ［20］ Piessen G, Messager M, Mirabel X, et al. Is there a role for surgery for patients with a complete clinical response after chemoradiation for esophageal cancer? An intentiontotreat casecontrol study［J］. Ann Surg, 2013, 258(5): 793-780. ［21］ Kogo M, Suzuki A, Sunaga T, et al. Scoring system for predicting recurrence after chemoradiotherapy including 5fluorouracil and platinum for patients with esophageal cancer［J］. Hepatogastroenterology, 2013, 60(128): 1979-1984. ［22］ Tan S, Kligerman S, Chen W, et al. Spatialtemporal ［18F］ FDGPET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy［J］. Int J Radiat Oncol Biol Phys, 2013, 85(5): 1375-1382. ［23］ Eng CW, Fuqua JL 3rd, Grewal R, et al. Evaluation of response to induction chemotherapy in esophageal cancer: is barium esophagography or PETCT useful?［J］. Clin Imaging, 2013, 37(3): 468-474. ［24］ Alexander BM, Wang XZ, Niemierko A, et al. DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer［J］. Int J Radiat Oncol Biol Phys, 2012, 83(1): 164-171. ［25］ Chen PC, Chen YC, Lai LC, et al. Use of germline polymorphisms in predicting concurrent chemoradiotherapy response in esophageal cancer［J］. Int J Radiat Oncol Biol Phys, 2012, 82(5): 1996-2003. ［26］ Pan JY, Ajani JA, Gu J, et al. Association of AuroraA (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation［J］. Cancer, 2012, 118(17): 4346-4353.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[5]	Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209.
[6]	Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156.
[7]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174.
[8]	Yue Hongyun, Zhang Baihong.Differentiation therapies in human cancers[J]. Journal of International Oncology, 2024, 51(2): 109-113.
[9]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.
[10]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei.Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients[J]. Journal of International Oncology, 2024, 51(1): 37-42.
[11]	Cui Tenglu, Lyu lu, Sun Pengfei.Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(9): 548-552.
[12]	Shandong Medical Association Multidisciplinary Joint Committee on Lung Cancer.Shandong Provincial Medical Association multidisciplinary standardized diagnosis and treatment guidelines for esophageal carcinoma （2023 Edition）[J]. Journal of International Oncology, 2023, 50(7): 385-397.
[13]	Li Chenxi, Zhao Hongwei.Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery[J]. Journal of International Oncology, 2023, 50(6): 342-347.
[14]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[15]	Lyu Lu, Sun Pengfei.Gut flora and cervical cancer[J]. Journal of International Oncology, 2023, 50(6): 373-376.

Concurrent chemoradiation for local advanced esophageal carcinoma

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments